Early changes in ocular biometry predict long-term treatment outcomes following repeated low-level red-light therapy
Zhou K, Ma X, Shen D, Zhao J, Sun X, Wei W
Photodiagnosis and photodynamic therapy · 1 cita
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Estudio de cohortes (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2026-02-26 · Photodiagnosis Photodyn Ther · vol. 58 · pág. 105414
- Editorial
- Elsevier BV
- Citado
- 1 cita · más que el 93% de estudios similares · 5.5× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 42 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY-NC-ND
- Áreas de investigación
- Ophthalmology and Visual Impairment Studies · Retinopathy of Prematurity Studies · Corneal surgery and disorders
- Palabras clave
- Clinical Practice, Baseline (sea), Clinical trial, Eye disease, MEDLINE
- MeSH
- humans, myopia, prognosis, treatment outcome, photochemotherapy, retrospective studies, biometry, child, female, male, axial length, eye, red light
6 autores
- Kun Zhou🇨🇳Shanxi Medical University; Microbiology Institute of Shaanxi; Shanxi Provincial People’s Hospital
- Xiaohuan Ma🇨🇳Shanxi Medical University; Microbiology Institute of Shaanxi; Shanxi Provincial People’s Hospital
- Di Shen🇨🇳Shanxi Medical University; Microbiology Institute of Shaanxi; Shanxi Provincial People’s Hospital
- Junhong Zhao🇨🇳Shanxi Medical University; Microbiology Institute of Shaanxi; Shanxi Provincial People’s Hospital
- Xiyu Sun🇨🇳 · autor de correspondenciaShanxi Medical University; Microbiology Institute of Shaanxi; Shanxi Provincial People’s Hospital
- Wei Wei🇨🇳 · autor de correspondenciaMicrobiology Institute of Shaanxi
Resumen
El texto original del estudio, en el idioma en que se publicó.
Purpose
Repeated low-level red-light (RLRL) therapy has emerged as a promising intervention for pediatric myopia control. However, substantial inter-individual variability in treatment response limits its clinical applicability. Reliable tools for early identification of long-term responders remain limited. This study aimed to develop a prognostic model based on early axial length (AL) dynamics to predict long-term myopia control outcomes in children undergoing RLRL therapy.
Methods
This retrospective cohort study included myopic children treated with RLRL therapy at Xi'an No.1 Hospital between August 2022 and December 2025. Participants were classified into good- and poor-prognosis groups based on yearly AL change (≤ -0.06 vs. > -0.06 mm/year). Demographic characteristics, baseline spherical equivalent (SE), subfoveal choroidal thickness (sChT), and ocular biometric parameters at baseline and at 1 and 3 months post-treatment were collected. Univariable logistic regression was used to screen potential predictors, and nomograms were constructed for prognostic modeling.
Results
A total of 69 children were enrolled (35 good-prognosis, 34 poor-prognosis). Significant differences were observed in baseline SE, AL, 1-month AL change, 3-month AL change, and the AL change rate over the first 3 months (all P < 0.05). The nomogram incorporating age, sex, and 3-month AL change showed the highest predictive performance, with an AUC of 0.961. No serious adverse events were observed during follow-up.
Conclusions
RLRL therapy is effective and safe for controlling myopia progression in children. Early AL dynamics, combined with baseline ocular parameters, provide strong predictive power for long-term outcomes, supporting individualized myopia management and risk-stratified clinical decision-making.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-ND).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.